Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD.siNeg.DSPE-PEG-M2pep
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**CD.siNeg.DSPE-PEG-M2pep** is an experimental **M2pep-targeted cyclodextrin-based siRNA nanoparticle** used as a **negative control construct** in prostate cancer tumor microenvironment studies. It consists of an amphiphilic cationic beta-cyclodextrin nanoparticle decorated with **DSPE-PEG-M2pep**, an M2 macrophage-targeting peptide conjugate, and loaded with **non-targeting control siRNA** rather than therapeutic CSF-1R siRNA. The platform was developed in an academic research setting to target tumor-associated M2 macrophages and evaluate targeted delivery performance; however, because the siRNA cargo is non-silencing, this specific construct is not itself the active therapeutic candidate but a comparator formulation for the corresponding CSF-1R siRNA nanoparticle system in preclinical prostate cancer research.
- Other names
- M2pep-modified cyclodextrin-siNeg nanoparticlesM-2pep-modified cyclodextrin-siNeg nanoparticlesM 2pep-modified cyclodextrin-siNeg nanoparticlesnegative control siRNA-loaded M2pep-targeted cyclodextrin nanoparticles
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)M2pep-R (M2-polarized macrophage surface receptor (M2pep receptor))
Beyond the preview
Go deeper on CD.siNeg.DSPE-PEG-M2pep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD.siNeg.DSPE-PEG-M2pep.